MX2012004420A - Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes. - Google Patents

Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.

Info

Publication number
MX2012004420A
MX2012004420A MX2012004420A MX2012004420A MX2012004420A MX 2012004420 A MX2012004420 A MX 2012004420A MX 2012004420 A MX2012004420 A MX 2012004420A MX 2012004420 A MX2012004420 A MX 2012004420A MX 2012004420 A MX2012004420 A MX 2012004420A
Authority
MX
Mexico
Prior art keywords
treating diabetes
pharmaceutical use
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
MX2012004420A
Other languages
English (en)
Spanish (es)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012004420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2012004420A publication Critical patent/MX2012004420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012004420A 2009-10-15 2010-10-11 Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes. MX2012004420A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
MX2012004420A true MX2012004420A (es) 2012-05-08

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004420A MX2012004420A (es) 2009-10-15 2010-10-11 Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.

Country Status (25)

Country Link
US (1) US8383642B2 (enExample)
EP (1) EP2488500A1 (enExample)
JP (1) JP2013508279A (enExample)
KR (1) KR20120051777A (enExample)
CN (1) CN102574807A (enExample)
AR (1) AR078522A1 (enExample)
AU (1) AU2010307094A1 (enExample)
BR (1) BR112012008889A2 (enExample)
CA (1) CA2777775A1 (enExample)
CL (1) CL2012000921A1 (enExample)
CO (1) CO6531458A2 (enExample)
CR (1) CR20120177A (enExample)
DO (1) DOP2012000105A (enExample)
EA (1) EA201270560A1 (enExample)
EC (1) ECSP12011799A (enExample)
IL (1) IL218344A0 (enExample)
MA (1) MA33662B1 (enExample)
MX (1) MX2012004420A (enExample)
NZ (1) NZ598972A (enExample)
PE (1) PE20121437A1 (enExample)
PH (1) PH12012500705A1 (enExample)
TN (1) TN2012000152A1 (enExample)
TW (1) TW201124415A (enExample)
WO (1) WO2011046851A1 (enExample)
ZA (1) ZA201202560B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010227245B2 (en) 2009-03-23 2015-09-10 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
CA2785674A1 (en) 2009-12-25 2011-06-30 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
PL2683251T3 (pl) 2011-03-11 2021-12-13 Intercontinental Great Brands Llc Sposób wytwarzania wielowarstwowych wyrobów cukierniczych
TW201247636A (en) 2011-04-27 2012-12-01 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivatives
EP2716636A4 (en) 2011-04-28 2014-11-26 Mochida Pharm Co Ltd CYCLIC AMIDE DERIVATIVE
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
EA026913B1 (ru) 2012-11-16 2017-05-31 Бристол-Майерс Сквибб Компани Дигидропиразольные модуляторы gpr40
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CA2928097A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
US10821110B2 (en) * 2014-10-17 2020-11-03 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316559T3 (es) * 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
JP3856815B2 (ja) * 2003-04-04 2006-12-13 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体アゴニストとしてのアシル化スピロピペリジン誘導体
MXPA06005038A (es) * 2003-11-04 2007-12-12 Elixir Pharmaceuticals Inc Compuestos terapeuticos y usos de los mismos.
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
CA2621949A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
MX2010004435A (es) 2007-10-26 2010-05-13 Japan Tobacco Inc Compuestos espiro y uso farmaceutico de los mismos.
US8158792B2 (en) * 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
AU2010307094A1 (en) 2012-04-19
IL218344A0 (en) 2012-04-30
PH12012500705A1 (en) 2012-10-29
ZA201202560B (en) 2013-09-25
PE20121437A1 (es) 2012-10-26
EA201270560A1 (ru) 2012-09-28
KR20120051777A (ko) 2012-05-22
CO6531458A2 (es) 2012-09-28
CA2777775A1 (en) 2011-04-21
TN2012000152A1 (en) 2013-12-12
WO2011046851A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
US20110092531A1 (en) 2011-04-21
CN102574807A (zh) 2012-07-11
MA33662B1 (fr) 2012-10-01
TW201124415A (en) 2011-07-16
JP2013508279A (ja) 2013-03-07
AR078522A1 (es) 2011-11-16
ECSP12011799A (es) 2012-07-31
US8383642B2 (en) 2013-02-26
CR20120177A (es) 2012-06-06
CL2012000921A1 (es) 2012-09-14
EP2488500A1 (en) 2012-08-22
DOP2012000105A (es) 2013-01-31
BR112012008889A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TN2012000248A1 (en) Novel spiropiperidine compounds
SG178952A1 (en) Chemical compounds
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2010009736A (es) Compuesto heterociclico.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
GB0812642D0 (en) Compounds
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2011011776A (es) Nuevos profarmacos de triptolite.
MX2011008289A (es) Tabletas para terapia combinada.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2010006218A (es) Compuestos organicos.
JO2979B1 (en) Cyclopropyl compounds
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
TN2010000397A1 (en) Heterocyclic compounds
WO2012008765A3 (ko) 암 치료 또는 예방용 약학 조성물
UA87608C2 (uk) Спосіб отримання ціанометилпіримідинів
UA60840U (ru) Способ лечения больных сахарным диабетом

Legal Events

Date Code Title Description
FA Abandonment or withdrawal